Lineage Cell Therapeutics

Brian Culley, CEO 

Oct. 12 | 2:15pm | UBC Ballroom 

Carlsbad, CA 


In-person Presentation 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. Lineage develops and manufactures specialized, terminally differentiated human cells developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs include five allogeneic product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy, being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced for immuno-oncology and infectious disease; (iv) ANP1, an auditory neuronal progenitor cell therapy; and (v) PNC1, a photoreceptor neural cell therapy. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions